Syngene International Ltd.

NSE: SYNGENE · Healthcare

₹376.00

as of 28 Sep 2026

AI verdict · 28 Sep 2026

Bearish 68% confidence

Confirmed Q1 earnings collapse (-106% EPS, -28% revenue) and 33% relative underperformance vs NIFTY outweigh recovery hopes; no management…

Strongest bull point

Biologics inventory correction and Librela client headwinds are cyclical, not structural; dividend maintenance and proximity to 52-week lows suggest capitulation opportunity if H2 FY27 shows recovery.

Strongest bear point

Negative earnings, severe revenue contraction, and stock-specific underperformance confirm operational deterioration; thin volume near 52-week lows indicates capitulation is incomplete with further downside risk.

Technical Forecast · next 10 trading days

Expected

₹380.12 +1.1%

Range

₹379.40 – ₹381.83

Technical Forecast Fundamental Debate

Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.

Every call on SYNGENE, misses included

Bearish 28 Sep 2026 → now Scores 28 Oct 2026

₹376.00 → ₹376.00 0.0%

Our accuracy

Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.

How we score →

More Healthcare